Inhibrx Biosciences Inc
inhibrx.comWhat Do They Do?
Develops biologic drug candidates for cancer and other serious diseases, using protein engineering to build a clinical pipeline of therapies.
10-K for FY2025, filed Mar 19, 2026We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary…View ↗
Our current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize our multivalent formats…View ↗
We are currently investigating ozekibart in chondrosarcoma, Ewing sarcoma, and colorectal cancer. These are some of the most aggressive…View ↗
How Do They Make Money?
Historically, it has received money through license and collaboration agreements and grants. Partners may pay license and upfront fees, reimburse research costs, make milestone payments, and pay royalties on product sales; grants come from government agencies and private not-for-profit organizations.
10-K for FY2025, filed Mar 19, 2026The Company has historically generated revenue from its license and collaboration agreements with partners, as well as from grants from…View ↗
The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the…View ↗
Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments…View ↗
$1.3M
-
10-K for FY2025, filed Mar 19, 2026
$1.3M ↗
Who Are Their Customers?
Partners fund research and development collaborations and license agreements; government agencies and private not-for-profit organizations provide grants.
10-K for FY2025, filed Mar 19, 2026
Do Revenues Turn Into Profits?
No. It lost $140.1M in FY2025.
10-K for FY2025, filed Mar 19, 2026
−$135MView ↗
10-K for FY2025, filed Mar 19, 2026
−$140.1MView ↗
10-K for FY2025, filed Mar 19, 2026
−$129.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$36.7MView ↗
- ▲ +28% (Loss)
- vs −$28.7M in Q2 FY2025
-
Sep 8, 2026
Reports Phase 2 HNSCC results for INBRX-106
Inhibrx plans to expand the study and then start its Phase 3 portion.
Sources
8-K, filed Sep 8, 2026
On September 8, 2026, Inhibrx announced the primary endpoint results from the randomized and controlled Phase 2 portion of its HexAgon…View ↗
-
Jun 15, 2026
FDA accepts ozekibart application for review
The FDA set an April 14, 2027 review goal date.
Sources
8-K, filed Jun 15, 2026
On June 15, 2026, Inhibrx Biosciences, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration…View ↗
Who Do They Compete With?
Competes with Crescendo Biologics, Molecular Partners, Precirix, Affibody Medical, Numab Therapeutics, GT Biopharma, Sanofi, Regeneron Pharmaceuticals, Adimab, Genmab, Macrogenics, Merus, Amgen, Xencor, Zymeworks, AstraZeneca, F. Hoffmann-La Roche, Pfizer, Merck &, and Novartis
10-K for FY2025, filed Mar 19, 2026Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Crescendo Biologics Ltd.…View ↗
Loading...
